Posted by Michael Wonder on 12 Jun 2024
Farxiga approved in the US for the treatment of paediatric type 2 diabetes mellitus
12 June 2024 - Approval based on results from T2NOW, one of the largest paediatric type 2 diabetes Phase 3 trials to date.
AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US FDA to improve glycaemic control in paediatric patients with type 2 diabetes aged 10 years and older.
